文献速递冠心病血脂与心血管预防

血浆红外分子指纹分层冠心病残余风险并反映克隆性造血相关生物学

Plasma infrared molecular fingerprinting stratifies residual risk in coronary artery disease and reflects clonal haematopoiesis-associated biology.
PubMed 文献 · Eur Heart J · 2026-07-29

外部验证在三个独立队列中重现了预期风险模式和共病关联。

要点

  • IMF+年龄对CAD患者死亡风险的区分度优于SMART2评分,C指数0.79 vs 0.74。
  • IMF风险分层清晰分离生存曲线,死亡率从低危3%升至高危27%。
  • 高风险层富集CHIP携带者,尤其剪接体突变,提示反映克隆性造血生物学。

核心结论

  • 血浆IMF可快速、低成本、无需测序地评估CAD残余死亡风险,优于指南评分并反映CHIP相关生物学。

研究设计与样本

  • 发现队列纳入1341例冠脉造影确诊的CAD患者(平均年龄73岁,76%男性),随访至10.7年。
  • 测量血浆IMF光谱、全面临床数据及13个CHIP驱动基因的靶向测序。
  • 采用惩罚Cox模型使用IMF特征,与指南推荐的SMART2评分进行基准比较。
  • 外部验证在三个独立队列(PRECAD2 474人;KORA 3044人;Lasers4Life 2123人)中进行。

主要发现

  • 决策曲线显示在临床阈值范围内净获益更大。
  • 较高风险层富集CHIP携带者,尤其剪接体突变。
  • 外部验证重现了预期风险模式和共病关联。

关键数值与推荐

  • 靶向测序覆盖13个CHIP驱动基因。

临床怎么用

  • IMF可作为无需测序的残余风险分层工具,辅助CAD二级预防的精准管理。
  • IMF风险分层可能识别CHIP相关高风险患者,为生物学导向的试验设计提供平台。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Residual cardiovascular risk remains substantial in patients with coronary artery disease (CAD) despite optimal secondary prevention. Clonal haematopoiesis of indeterminate potential (CHIP) contributes causally to this risk but requires sequencing for detection. Plasma infrared molecular fingerprinting (IMF), a spectroscopy-based assay, was evaluated as a sequencing-free tool for residual risk stratification and CHIP-aligned phenotyping. METHODS: The discovery cohort included 1341 patients with angiographically confirmed CAD (mean age 73 years, 76% male) followed for up to 10.7 years. Plasma IMF spectra, comprehensive clinical data, and targeted sequencing of 13 CHIP driver genes were measured. Penalized Cox models using IMF features were benchmarked against the guideline-recommended SMART2 score. Model performance was assessed by discrimination, reclassification, calibration, and decision curve analyses. External validation was performed in three independent cohorts (PRECAD2, 474 individuals; KORA, 3044 individuals; Lasers4Life, 2123 individuals). RESULTS: IMF+Age demonstrated superior mortality discrimination over SMART2 (C-index 0.79 vs 0.74, P < .01) and significant reclassification improvement. Decision curves showed greater net benefit across clinical thresholds. IMF-derived risk strata showed clear separation of Kaplan-Meier survival curves (log-rank P < .001), with mortality increasing from 3% (low-risk) to 27% (high-risk). Higher-risk strata were enriched for CHIP carriers, particularly spliceosome mutations. External validation reproduced expected risk patterns and comorbidity associations. CONCLUSIONS: Plasma IMF provides rapid, low-cost, sequencing-free assessment of residual mortality risk in CAD, outperforming guideline-based scores while reflecting CHIP-associated biology. IMF offers a scalable phenotypic platform for precision secondary prevention and biology-guided trial design.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. von Scheidt M, Eissa T, Krefting J, et al. Plasma infrared molecular fingerprinting stratifies residual risk in coronary artery disease and reflects clonal haematopoiesis-associated biology. Eur Heart J. 2026. PMID: 42522903. doi:10.1093/eurheartj/ehag587

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。